ClinicalTrials.gg
CompletedNCT02225093Updated Jun 27, 2017

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

A Phase 1 interventional study of Caffeine and Dextromethorphan in Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine and Prostate Cancer, sponsored by Astellas Pharma Europe B.V.. Completed at 1 site in Moldova, Republic of. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-27.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2013, registered Aug 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Prostatic Neoplasms by Astellas Pharma Inc — 5 open to participants now, 7 under way, 1 of them phase 3. Prostatic Neoplasms · Astellas Pharma Inc.

Enrollment
35th of 39
12 · median 67
Started
2013
with 3 others
Phase 1
12 of 53
4 open now
Registered
30th of 53
by date

Among the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc, this one is the 35th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2013, is one of 12 in phase 1, and was the 30th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Prostatic Neoplasms by Astellas Pharma Inc, or all of them as a file.
02

Study summary

This study evaluates how once daily enzalutamide affects the metabolism of caffeine and dextromethorphan in men with prostate cancer by measuring concentrations of these drugs and their metabolites in plasma.

Read the detailed description

This is an open-label, fixed-sequence, crossover drug-drug interaction study in subjects with prostate cancer.

Screening takes place between Day -28 and Day -7, and subjects are admitted to the clinic on Day -1 where they remain until Day 4.

On Day 1, they receive a single oral cocktail containing caffeine and dextromethorphan plus a dose of enzalutamide placebo in order to assess possible effects of excipients of the enzalutamide formulation. On Days 1 to 3 blood samples for pharmacokinetic (PK) assessment are collected. From Days 4 to 54, (or Day 55 if the subject rolls over into the extension study) the subjects take a daily oral dose of enzalutamide. On Day 28, the subjects return to the clinic where a plasma sample is taken to determine enzalutamide PK exposure. From Days 52 to 55 they are re-admitted to the clinic where a plasma sample is collected on Day 52 for enzalutamide PK exposure.On Day 53, subjects receive a single oral cocktail of caffeine and dextromethorphan concomitantly with enzalutamide. PK samples are collected from Days 53 to 55.

From Day 55 onwards, subjects experiencing clinical benefit may roll over into an extension study. Only subjects who enroll into the extension study continue to receive enzalutamide otherwise daily dosing with enzalutamide is discontinued on Day 54.

An End of Study Visit (ESV) takes place approximately 30 days (±7 days) after the last dose of enzalutamide.

03

Conditions studied

  • Pharmacokinetics of Dextromethorphan
  • Pharmacokinetics of Caffeine
  • Prostate Cancer

Browse trials for

Keywords

  • Safety
  • Dextromethorphan
  • CYP2D6
  • Phase 1
  • Prostate cancer
  • CYP1A2
  • Pharmacokinetics
  • Drug-drug interactions
  • Caffeine
  • Enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a male aged 18 years old or older (at screening) with confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a /adjuvant setting). Subjects may be on ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or have undergone prior bilateral orchiectomy at screening.
  • Subject has progressive disease by prostate-specific antigen (PSA) or imaging.
  • Subject has received no more than 2 prior chemotherapy regimens.
  • Subject has an (ECOG) performance status of 0-2.
  • Male subject must use a condom if having sex with a pregnant woman.
  • Male subject and their female spouse/partners who are of must use 2 acceptable methods of starting at screening and continuing throughout the study period and for 3 months after final study drug administration.
  • Subject has an estimated of at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Subject has confirmed CYP2D6 poor metabolizer, or CYP2D6 ultrarapid metabolizer status based on genotyping analysis.
  • Subject has known in the liver or any hepatic disorder that could affect drug metabolism deemed by the investigator after discussion with the sponsor.
  • Subject has undergone major surgery within 4 weeks prior to day 1.
  • Subject received treatment with chemotherapy within 4 weeks prior to enrollment (day 1 visit) or plans to initiate treatment with chemotherapy during the study.
  • Subject uses concomitant medications that are potent inducers and/or inhibitors of CYP1A2, CYP2C8, CYP2D6, or .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    1:Caffeine, Dextromethorphan and Enzalutamide

    1-sequence crossover here

    Drug: Caffeine · Drug: Dextromethorphan · Drug: Enzalutamide · Drug: Enzalutamide Placebo to Match (PTM)

Interventions

  • Oral

    Also known as: CYP1A2 substrate

  • Oral /.L

    Also known as: CYP2D6 substrate

  • Oral

    Also known as: Xtandi, MDV3100, ASP9785

  • DrugEnzalutamide Placebo to Match (PTM)

    Oral

06

What researchers measure

Primary outcomes

  1. PK measured by Pharmacokinetic parameter Maximum concentration (Cmax)

    For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.

    Time frame: Day 1 and Day 53 (28 times)

  2. PK measured by Pharmacokinetic parameter Area under the curve (AUC) from the time of dosing to the last measurable concentration (AUC0-t)

    For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.

    Time frame: Day 1 and Day 53 (28 times)

  3. PK measured by PK parameter area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-inf)

    For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.

    Time frame: Day 1 and Day 53 (28 times)

Secondary outcomes

  1. PK measured by PK parameters tmax, terminal elimination half-life (t1/2), apparent total systemic clearance after oral dosing (CL/F), apparent volume of distribution during terminal elimination phase (Vz/F) and extrapolated AUC (%AUC)

    Tmax is time to maximum concentration. These PK parameters will be measured for the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.

    Time frame: Day 1 and Day 53 (28 times)

  2. PK measured by PK parameters Cmax, AUC0-t, AUC0-inf, %AUC, tmax and t1/2

    For 1,7-dimethylxanthine (metabolite caffeine), dextrorphan (metabolite dextromethorphan).

    Time frame: Day 1 and Day 53 (28 times)

  3. PK measured by PK parameters Cmax, trough concentrations (Ctrough) at Days 28, 52, 53, 54 and 55, tmax, AUC during the time interval between consecutive dosing (AUCtau), CL/F (parent only) and peak-to-trough ratio (PTR)

    For Enzalutamide, N-desmethyl enzalutamide (M2) and sum of enzalutamide + M2.

    Time frame: Day 28 (± 1 day), and Days 52 to 55 (15 times)

  4. Safety and tolerability measured by vital signs, adverse events, laboratory assessments and electrocardiogram

    Time frame: Screening (Day -28 to Day -7) to ESV (>153 times)

07

Study locations

1 site
  • Arensia
    Chisinau, 2025, Moldova, Republic of
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Feb 2014, 4 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 4 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2014
First posted
Aug 26, 2014
StartActual
Oct 2, 2013
Primary completionActual
Feb 3, 2014
CompletionActual
Feb 3, 2014
Last update
Jun 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02225093
Collaborators
Medivation, Inc.
Responsible party
Sponsor
First posted
Aug 26, 2014
Start date
Oct 2, 2013
Primary completion
Feb 3, 2014
Completion
Feb 3, 2014
Last update
Jun 27, 2017

Study contacts

Medical Director
study director · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Caffeine · Dextromethorphan · Enzalutamide

Start the discussion